Overview

A Study of SYH2051 Monotherapy in Advanced Solid Tumors or in Combination With Radiotherapy in Locally Advanced Head and Neck Cancer

Status:
Recruiting
Trial end date:
2025-08-31
Target enrollment:
Participant gender:
Summary
This is an open-label, multicenter, dose-escalation phase I study to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor efficacy of SYH2051 in patients with advanced solid tumors or in combination with radiotherapy (RT) in patients with locally advanced head and neck cancer.
Phase:
Phase 1
Details
Lead Sponsor:
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.